Nelson Shu-Sang Yee, MD, PhD, RPh - Penn State Cancer Institute
Researcher Profile
Nelson Shu-Sang Yee, MD, PhD, RPh
Associate Professor, Department of Medicine
Professor, Department of Medicine
Division of Hematology and Oncology
Assistant Professor, Department of Medicine
Professor, Department of Medicine
Division of Hematology and Oncology
Assistant Professor, Department of Medicine
Scientific Program:Next-Generation Therapies
Disease Teams:
Cancer Institute, Gastrointestinal Cancer Team
Cancer Institute, Liver, Pancreas and Foregut Cancer Team
Cancer Institute, Liver, Pancreas and Foregut Cancer Team
Research Interests
- Therapeutics
- Neoplasms
- Pancreatic Neoplasms
- Adenocarcinoma
- Zebrafish
- Biomarkers
- Ion Channels
- Carcinoma
- Growth
- Mast Cells
- Exocrine Pancreas
- Hepatocellular Carcinoma
Clinical Trials
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (NRG-GI008)
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (KRYSTAL-1) (MRT849-001)
Micro/nano technology for extracellular vesicle isolation and towards non-invasive pancreatic cancer diagnosis
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
Cancer biobank for developing novel diagnostic biomarkers and therapeutic targets
A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy
Recent Publications
2024
Mareboina, M, Deng, E, Mouratidis, I, Yee, NS, Pitteloud, N, Georgakopoulos-Soares, I & Chartoumpekis, DV 2024, 'A review on cell-free RNA profiling: Insights into metabolic diseases and predictive value for bariatric surgery outcomes', Molecular Metabolism, vol. 87, 101987. https://doi.org/10.1016/j.molmet.2024.101987
Tsiatsianis, GC, Chan, CSY, Mouratidis, I, Chantzi, N, Tsiatsiani, AM, Yee, NS, Zaravinos, A, Kantere, V & Georgakopoulos-Soares, I 2024, 'Peptide absent sequences emerging in human cancers', European Journal of Cancer, vol. 196, 113421. https://doi.org/10.1016/j.ejca.2023.113421
Montgomery, A, Tsiatsianis, GC, Mouratidis, I, Chan, CSY, Athanasiou, M, Papanastasiou, AD, Kantere, V, Syrigos, N, Vathiotis, I, Syrigos, K, Yee, NS & Georgakopoulos-Soares, I 2024, 'Utilizing nullomers in cell-free RNA for early cancer detection', Cancer gene therapy, vol. 31, no. 6, pp. 861-870. https://doi.org/10.1038/s41417-024-00741-3
2023
Waldstein, S, Spengler, M, Pinchuk, IV & Yee, NS 2023, 'Impact of Colorectal Cancer Sidedness and Location on Therapy and Clinical Outcomes: Role of Blood-Based Biopsy for Personalized Treatment', Journal of Personalized Medicine, vol. 13, no. 7, 1114. https://doi.org/10.3390/jpm13071114
Linscott, MP, Markus, H, Sennett, M, Abendroth, C & Yee, NS 2023, 'Nab-Paclitaxel and Gemcitabine as First-Line Treatment of Metastatic Ampullary Adenocarcinoma with a Novel R-Spondin2 RNA Fusion and NTRK3 Mutation', Biomedicines, vol. 11, no. 8, 2326. https://doi.org/10.3390/biomedicines11082326
2022
Kumar, R, Tchelebi, L, Anker, CJ, Sharma, N, Bianchi, NA, Dragovic, J, Goodman, KA, Herman, JM, Jiang, Y, Jones, WE, Kennedy, TJ, Lee, P, Kundranda, M, Russo, S, Small, W, Suh, WW, Yee, N & Jabbour, SK 2022, 'American Radium Society (ARS) Appropriate Use Criteria (AUC) for Locoregional Gastric Adenocarcinoma: Systematic Review and Guidelines', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 45, no. 9, pp. 391-402. https://doi.org/10.1097/COC.0000000000000930
2021
Mohamed, A, Menon, H, Chulkina, M, Yee, NS & Pinchuk, IV 2021, 'Drug–microbiota interaction in colon cancer therapy: Impact of antibiotics', Biomedicines, vol. 9, no. 3, 259, pp. 1-13. https://doi.org/10.3390/biomedicines9030259
2020
Wheelden, M & Yee, NS 2020, 'Clinical evaluation of the safety and efficacy of trifluridine/tipiracil in the treatment of advanced gastric/gastroesophageal junction adenocarcinoma: Evidence to date', OncoTargets and Therapy, vol. 13, pp. 7459-7465. https://doi.org/10.2147/OTT.S216598
Yee, NS, Zhang, S, He, HZ & Zheng, SY 2020, 'Extracellular vesicles as potential biomarkers for early detection and diagnosis of pancreatic cancer', Biomedicines, vol. 8, no. 12, 581, pp. 1-20. https://doi.org/10.3390/biomedicines8120581
Yee, NS 2020, 'Liquid biopsy: A biomarker-driven tool towards precision oncology', Journal of Clinical Medicine, vol. 9, no. 8, 2556, pp. 1-3. https://doi.org/10.3390/jcm9082556
Schmitz, KH, Potiaumpai, M, Schleicher, EA, Wolf, LJ, Doerksen, SE, Drabick, JJ, Yee, NS, Truica, CI, Mohamed, AA, Shaw, BW & Farley, DC 2021, 'The exercise in all chemotherapy trial', Cancer, vol. 127, no. 9, pp. 1507-1516. https://doi.org/10.1002/cncr.33390
Shen, C, Thornton, JD, Newport, K, Schaefer, E, Zhou, S, Yee, NS, Dodge, D & Leslie, D 2020, 'Trends and patterns in the use of opioids among metastatic breast cancer patients', Scientific reports, vol. 10, no. 1, 21698. https://doi.org/10.1038/s41598-020-78569-8